RecruitingPhase 4NCT06745466
Disentangling the Effects of Daily Stress, Sleep, and Sex Hormones on Accelerated Vascular Aging in Midlife Women
University of Delawaren = 3015 Nov 2024 to est. Oct 2027
Estrogen · Premenopause
Ganirelix / Studies
Synthetic analog · 10 amino acids · 1,570.3 Da
Ganirelix studies and research data
PepBank has 55 ganirelix studies with results. All of them gave ganirelix, with 344 results, grouped by what the studies measured. In each group, results from studies in people come first. Data as of 2026-10-30.
Searches 344 results and 166 papers. Newer studies from Europe PMC
Results in people
258
75% of 344 results
Results in animals
51
15% of 344 results
Results in lab cells
35
10% of 344 results
From computer models
0
0% of 344 results
The molecule
Ganirelix identity
Identifiers, parent molecule, targets and development stage, from curated data.
Ganirelix is a ten-residue GnRH receptor antagonist. Its acetate injection inhibits premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation.
- Kind
- Synthetic analog · 10 residues
- Identifiers
- ChEMBLCHEMBL1251 (opens in a new tab)PubChem CID16130957 (opens in a new tab)UNIIIX503L9WN0 (opens in a new tab)DrugBankDB06785 (opens in a new tab)CAS124904-93-4
- Parent
- Analog of GonadorelinThe US label identifies substitutions from native GnRH at residues 1, 2, 3, 6, 8, and 10. UniProt P01148 identifies the human GnRH precursor. Its mature gonadorelin peptide occupies precursor residues 24-33. Ganirelix is a synthetic analog, not a native precursor fragment.
- Development
- Approved in the US and EU (Ganirelix acetate)An approved medicinal product exists. Availability and other indications can differ. Source (opens in a new tab)
Targets
| Target | Action | Evidence |
|---|---|---|
| Gonadotropin-releasing hormone receptorGNRHRP30968 (opens in a new tab) | Antagonist | Official prescribing information, mechanism of actionSource (opens in a new tab) |
Sequence and structure
Residues, differences from the parent, calculated properties and 3D structure. Source values and calculated values are shown separately.
Sequence
10 amino acids · 6 modifications
Residues 1 to 10:
SYLP
Alignment to Gonadorelin
Calculated from the two sequences. Curated notes are shown as given.
4 of 10 aligned residues identical (40%) · 6 non-canonical residues · Gonadorelin 1–10
- Top row: Gonadorelin (parent)
- Bottom row: Ganirelix
SYLP
- Same as parent
- Substituted
- Non-canonical or D-form
- Added
- Gap
- Modified side chain or end
Differences from the parent
- 1Parent 1 · analog 1Xaa → D-2-Nal · Non-canonical residueD-2-Nal
- 2Parent 2 · analog 2His → D-4-Cl-Phe · Non-canonical residueD-4-Cl-Phe
- 3Parent 3 · analog 3Trp → D-3-Pal · Non-canonical residueD-3-Pal
- 4Parent 6 · analog 6Gly → Xaa · Non-canonical residueN9,N10-diethyl-D-homoarginine
- 5Parent 8 · analog 8Arg → Xaa · Non-canonical residueN9,N10-diethyl-L-homoarginine
- 6Parent 10 · analog 10Gly → D-Ala · D-amino acidD-Ala
Basis: The US label identifies substitutions from native GnRH at residues 1, 2, 3, 6, 8, and 10. UniProt P01148 identifies the human GnRH precursor. Its mature gonadorelin peptide occupies precursor residues 24-33. Ganirelix is a synthetic analog, not a native precursor fragment.
Calculated from the two sequences with @pepdb/chem alignToParent (ungapped unless a gap scores higher). The record’s curated notes are shown as given.
Properties
From identity sources
- Formula
- C80H113ClN18O13
- Molecular weight
- 1,570.3 g/mol
- Monoisotopic mass
- 1,568.8423 Da
- GSRS UNII IX503L9WN0(opens in a new tab)retrieved 2026-10-27
- PubChem CID 16130957(opens in a new tab)retrieved 2026-10-27
- Curated Ganirelix acetate US label(opens in a new tab)retrieved 2026-10-27
Calculated from the sequence
Some values cannot be calculated. The sequence has a non-canonical residue (X). Residue tables cover only the 20 standard amino acids.
- Average mass
- Not calculated
- Monoisotopic mass
- Not calculated
- Isoelectric point (pI)
- Not calculated
- Net charge at pH 7.4
- Not calculated
- GRAVY (hydropathy)
- Not calculated
- Extinction coefficient, 280 nm (Cys reduced)
- 1,490 M⁻¹ cm⁻¹
- 5500 x Trp + 1490 x Tyr · Pace et al. 1995 (ExPASy ProtParam)
- No Trp: ExPASy reports more than 10 % error without Trp.
- Instability index
- Not calculated
- Aliphatic index
- Not calculated
- Boman index
- Not calculated
- Hydrophobic moment (μH)
- Not calculated
- 5 non-canonical residues (X) are not included in calculated values.
- D-amino acids have the same mass and charge as L forms. Hydrophobicity scales were measured on L forms.
- Defined and validated for proteins; use with care for short peptides.
- Assumes an ideal alpha helix. Many short peptides are not helical.
@pepdb/chem 0.2.0 · EMBOSS pKa set · ExPASy residue masses
Net charge by pH
No charge curve
The sequence has a non-canonical residue (X). Residue tables cover only the 20 standard amino acids.
Composition
- Hydrophobic20% (2)A L
- Aromatic10% (1)Y
- Polar10% (1)S
- Special10% (1)P
- Non-canonical50% (5)X
10 residues. Each residue counts in one class; F and W count as aromatic.
A Ala1 · 10%
I Ile0 · 0%
L Leu1 · 10%
M Met0 · 0%
V Val0 · 0%
F Phe0 · 0%
W Trp0 · 0%
Y Tyr1 · 10%
H His0 · 0%
K Lys0 · 0%
R Arg0 · 0%
D Asp0 · 0%
E Glu0 · 0%
N Asn0 · 0%
Q Gln0 · 0%
S Ser1 · 10%
T Thr0 · 0%
C Cys0 · 0%
G Gly0 · 0%
P Pro1 · 10%
X Xaa5 · 50%
3D structure
PredictedAlphaFold DB · P01148
Loads the 3D viewer (3Dmol.js, about 150 KB) and the model file from AlphaFold DB (EMBL-EBI).
2D structure
Draws the structure in your browser with RDKit (about 2.3 MB, loaded once).
SMILES fromPubChem CID 16130957(opens in a new tab)
CCNC(=NCCCC[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN=C(NCC)NCC)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(=O)N)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC3=CN=CC=C3)NC(=O)[C@@H](CC4=CC=C(C=C4)Cl)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)NC(=O)C)NCCResults by area
What the studies measured
People first in each area, then animals, then lab cells. Counts are exact and come from studies that gave the peptide.
Trials and papers
Newer studies
PepBank reads each paper before it shows the results. This search looks in Europe PMC for newer papers that PepBank has not read yet.
Status and safety
Data